Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma

Press/Media: Press / Media

Period2018 Oct 2

Media coverage

1

Media coverage

  • TitleStudy of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma
    Media name/outletClinical Trials.gov
    CountryUnited States
    Date18/10/2
    PersonsJinseok Kim